0I1B.LSE Enovis Corporation
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -1.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0I1B.LSE undervalued?
Graham numberThe Graham number of Enovis Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enovis Corporation fundamental analysis
No fundamental analysis for Enovis Corporation yet.
Enovis Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enovis Corporation
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy …
Full company profileEnovis Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Enovis Corporation annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.19B | 3.30B | 2.19B | 3.33B | 3.07B | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B | 2.34B |
| Gross Profit | 952M | 976M | 729M | 1.40B | 1.14B | 658M | 737M | 994M | 1.03B | 1.17B | 1.28B |
| Operating Income | 273M | 321M | 181M | 325M | 235M | -23.2M | -26.7M | -65.7M | -3.73M | 3.01M | 85.1M |
| EBITDA | 349M | 160M | 330M | 409M | 412M | 95.0M | 226M | 170M | -480M | 297M | 315M |
| Net Income | 128M | -157M | 140M | -542M | 51.4M | 62.6M | -15.0M | -33.3M | -825M | -1.18B | -19.9M |
| EPS | 3.12 | -3.83 | 3.48 | -12 | 1.11 | 1.22 | -0.28 | -0.61 | -15 | -21 | -0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 6.34B | 6.71B | 6.62B | 7.39B | 7.35B | 8.52B | 4.27B | 4.51B | 4.72B | 3.83B | 3.77B |
| Total Liabilities | 3.25B | 2.98B | 3.14B | 3.90B | 3.76B | 3.85B | 823M | 1.09B | 2.15B | 2.34B | 2.29B |
| Shareholders' Equity | 2.90B | 3.50B | 3.27B | 3.44B | 3.54B | 4.62B | 3.45B | 3.42B | 2.56B | 1.49B | 1.48B |
| Cash & Short-term Investments | 209M | 412M | 77.2M | 110M | 101M | 680M | 24.3M | 36.2M | 48.2M | 36.4M | 12.6M |
| Total Debt | 1.29B | 1.06B | 1.20B | 2.49B | 2.41B | 2.16B | 335M | 536M | 1.43B | 1.44B | 1.37B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 247M | 219M | 226M | 131M | 302M | 356M | -55.9M | 135M | 114M | 217M | 198M |
| Capital Expenditure | 63.3M | 68.8M | 69.6M | 125M | 115M | 104M | 105M | 122M | 181M | 197M | 193M |
| Free Cash Flow | 184M | 150M | 157M | 5.55M | 187M | 252M | -161M | 12.8M | -67.2M | 19.9M | 4.57M |
| Ratios | |||||||||||
| ROE | 4.4% | -4.5% | 4.3% | -15.7% | 1.5% | 1.4% | -0.4% | -1.0% | -32.2% | -79.4% | -1.3% |
| ROA | 2.0% | -2.3% | 2.1% | -7.3% | 0.7% | 0.7% | -0.4% | -0.7% | -17.5% | -30.8% | -0.5% |
| Net Profit Margin | 4.0% | -4.8% | 6.4% | -16.3% | 1.7% | 4.4% | -1.0% | -1.9% | -39.2% | -52.6% | -0.8% |
| Debt to Equity | 0.45x | 0.30x | 0.37x | 0.72x | 0.68x | 0.47x | 0.10x | 0.16x | 0.56x | 0.97x | 0.93x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Enovis Corporation dividends
Enovis Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 0.333333:1 on Apr 5, 2022.
Who owns Enovis Corporation
- Insiders 1.64%
- Institutions 98.36%
- Public & others 0.00%
- Free float 52.8M
Enovis Corporation company profile
- Company name
- Enovis Corporation
- Ticker
- 0I1B.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 7,802
- Fiscal year end
- December
- Address
- 2900 Lake Vista Drive, Lewisville, TX, United States, 75067
- Phone
- 302 252 9160
- Website
- enovis.com
About Enovis Corporation
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.
Enovis Corporation management
10- Mr. Damien McDonaldCEO & Director · born 1965
- Mr. Phillip Benjamin BerrySenior VP & CFO · born 1979
- Ms. Patricia A. LangAdvisor · born 1959
- Mr. Terry D. RossGroup President Prevention & Recovery · born 1970
- Mr. Louie VogtGroup President of Reconstructive · born 1981
- Mr. John KlecknerVP, Controller & Chief Accounting Officer · born 1977
- Mr. Oliver EngertChief Administrative Officer · born 1965
- Mr. Kyle William RoseVice President of Investor Relations
- Mr. Bradley J. Tandy J.D.Senior VP & Chief Legal Officer · born 1959
- Ms. Laura SingletonSenior VP & Chief Human Resources Officer